CoChat

An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

Open access
Ligueros‐Saylan, M., Foley, J. E., Schweizer, A., Couturier, A., Kothny, W. · 2010 · Diabetes, Obesity and Metabolism
Cited by 145

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Aim: To assess the safety of vildagliptin versus all comparators (ACs) with regard to organs, systems or tissues of particular interest in type 2 diabetes (T2DM) and areas of potential concern with dipeptidyl peptidase‐IV (DPP‐4) inhibitors. Methods: Data were pooled from 38 studies where vildagliptin was given for ≥12 to > 104 weeks in patients with T2DM. Absolute and exposure‐adjusted incidence rates and Peto odds ratios (ORs) versus ACs with corresponding 95% confidence intervals (CI) were calculated. Results: There were > 7000 subject‐years of exposure (SYE) to vildagliptin 50 mg bid and > 6500 SYE to ACs. For mild hepatic enzyme elevations with and without elevated bilirubin levels, the ORs for vildagliptin 50 mg bid were 1.24 (95% CI: [0.80, 1.93]) and 1.19 (95% CI: [0.29, 4.90]), respectively. The exposure‐adjusted incidences of markedly elevated hepatic enzymes and for enzyme elevations with bilirubin ≥ 2× ULN with vildagliptin 50 mg bid were ≤ those in the ACs group. For hepatic and pancreatitis‐related AEs, the ORs for vildagliptin 50 mg bid were 0.87 (95% CI: [0.64, 1.19]) and 0.70 (95% CI: [0.26, 1.88]), respectively, and for any AE in the infections and infestations SOC, this was 1.04 (95% CI: [0.96, 1.13]). The incidences of skin‐related AEs were low and the risk with vildagliptin 50 mg bid was not significantly different from ACs [(OR = 1.10 (95% CI: [0.80, 1.51])]. Conclusions: The present meta‐analyses indicate that vildagliptin was not associated with increased risk of hepatic events or hepatic enzyme elevations indicative of drug‐induced liver injury, pancreatitis, infections or skin‐related toxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2010.01214.x

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 145

Metadata

Authors
Ligueros‐Saylan, M., Foley, J. E., Schweizer, A., Couturier, A., & Kothny, W.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2010-04-20
Volume
12
Issue
6
Pages
495-509
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1983130067
Cited by
145
References
8
FWCI
16.73
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. https://app.cochat.ai/papers/10.1111/j.1463-1326.2010.01214.x
The paper
Ligueros‐Saylan, M., Foley, J. E., Schweizer, A., Couturier, A., & Kothny, W. (2010). An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2010.01214.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.